HOOKIPA Pharma Inc. (HOOK)
收市後：
| 前收市價 | 0.7650 |
| 開市 | 0.8240 |
| 買盤 | 0.8190 x 100 |
| 賣出價 | 0.8855 x 100 |
| 今日波幅 | 0.7260 - 0.8670 |
| 52 週波幅 | 0.4100 - 2.0500 |
| 成交量 | |
| 平均成交量 | 554,766 |
| 市值 | 82.068M |
| Beta 值 (5 年，每月) | 1.02 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.9600 |
| 業績公佈日 | 2024年5月09日 - 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 4.70 |
BenzingaWhy Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cancers. In January, Roche terminated the collaboration and licensing agreement for HOOKIPA’s HB-700 program in KRAS mutated cancers. HOOKIPA’s HB-700 program is designed to treat KRAS-mutated lung, colorectal, pancreatic, and other cancers by targeting the five most prevalent KRAS mutat
ZacksHOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
HOOKIPA Pharma (HOOK) delivered earnings and revenue surprises of 45% and 105.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksAbsci Corporation (ABSI) Surges 10.0%: Is This an Indication of Further Gains?
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
